Evaluation of the diagnostic algorithm consisting of enzyme immunoassay for toxins and polymerase chain reaction, for the diagnosis of Clostridium difficile-associated diarrhoea

Abstract A total of 1631 stool specimens were tested for Clostridium difficile toxins A and B using an enzyme immunoassay (EIA). C. difficile toxin was detected in 191 (11.7%, 191/1631) cases by EIA. Among the remaining 1440 cases, 102 cases in patients with either antibiotic-associated diarrhoea or hospitalized patients with unexplained leukocytosis (> 15,000/mm3) and fever (≥ 38°C) even though they did not meet the criteria for diarrhoea, were further assessed using a polymerase chain reaction (PCR) for the toxin B gene (tcdB). Thirty-four cases were tcdB-positive (33.3%, 34/102). A total of 225 cases (13.8%, 225/1631) had a stool test result positive for C. difficile toxins. Among these, 145 cases were diagnosed with C. difficile-associated diarrhoea (CDAD): 80.7% (117/145) using the EIA and 19.3% (28/145) using the PCR. In our study, the 2-test algorithm including EIA-toxin assay and PCR test made a more accurate diagnosis of CDAD. Furthermore, the application of clinical situations may be effective in the selection of patients who need confirmatory testing.

[1]  P. Hawkey,et al.  A two-stage algorithm for Clostridium difficile including PCR: can we replace the toxin EIA? , 2012, The Journal of hospital infection.

[2]  Guang-xi Li,et al.  Clinical practice guidelines for Clostridium difficile infection in adults:2010 update by the Society for Healthcare Epidemiology of America(SHEA)and the Infectious Diseases Society of America(IDSA) , 2011 .

[3]  P. Gilligan,et al.  Clostridium difficile testing algorithms: what is practical and feasible? , 2009, Anaerobe.

[4]  K. Carroll,et al.  Yield of Stool Culture with Isolate Toxin Testing versus a Two-Step Algorithm Including Stool Toxin Testing for Detection of Toxigenic Clostridium difficile , 2007, Journal of Clinical Microbiology.

[5]  Melinda B Davis,et al.  A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  J. Fordtran Colitis Due to Clostridium Difficile Toxins: Underdiagnosed, Highly Virulent, and Nosocomial , 2006, Proceedings.

[7]  Michael A. John,et al.  Clinical usefulness of components of the Triage immunoassay, enzyme immunoassay for toxins A and B, and cytotoxin B tissue culture assay for the diagnosis of Clostridium difficile diarrhea. , 2003, American journal of clinical pathology.

[8]  F. Barbut,et al.  Epidemiology of Recurrences or Reinfections ofClostridium difficile-Associated Diarrhea , 2000, Journal of Clinical Microbiology.

[9]  J. Silva Antibiotic-associated colitis. , 1984, The Western journal of medicine.

[10]  N. Sullivan,et al.  Enzyme-linked immunosorbent assay for Clostridium difficile toxin A , 1983, Journal of clinical microbiology.